These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 19699696

  • 41. Sorafenib: in hepatocellular carcinoma.
    Simpson D, Keating GM.
    Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
    [Abstract] [Full Text] [Related]

  • 42. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
    Gadaleta-Caldarola G, Divella R, Mazzocca A, Infusino S, Ferraro E, Filippelli G, Daniele A, Sabbà C, Abbate I, Brandi M.
    Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
    [No Abstract] [Full Text] [Related]

  • 43. Contrast-enhanced ultrasonography for evaluating antiangiogenic treatment in hepatocellular carcinoma. A long way from research to clinical practice.
    Spârchez Z.
    Med Ultrason; 2012 Jun; 14(2):85-6. PubMed ID: 22675706
    [No Abstract] [Full Text] [Related]

  • 44. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T, Pang R, Chan P, Poon RT.
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [Abstract] [Full Text] [Related]

  • 45. Sorafenib.
    Hasskarl J.
    Recent Results Cancer Res; 2010 Sep; 184():61-70. PubMed ID: 20072831
    [Abstract] [Full Text] [Related]

  • 46. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z.
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [Abstract] [Full Text] [Related]

  • 47. [The hepatocellular carcinoma: alternative therapeutical strategies].
    Spangenberg HC, Thimme R, Mohr L, Blum HE.
    Zentralbl Chir; 2007 Aug; 132(4):322-7. PubMed ID: 17724635
    [Abstract] [Full Text] [Related]

  • 48. [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].
    Takeda Y, Nakahira S, Takeno A, Suzuki R, Nakata K, Okishiro M, Egawa C, Okamura S, Miki H, Kato T, Takatsuka Y, Tamura S.
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2496-8. PubMed ID: 22202425
    [Abstract] [Full Text] [Related]

  • 49. [Targeted therapies in hepatocellular carcinoma].
    Bouattour M, Marijon H, Dreyer C, Faivre S, Raymond E.
    Presse Med; 2010 Nov; 39(7-8):753-64. PubMed ID: 20378303
    [Abstract] [Full Text] [Related]

  • 50. [Chemotherapy].
    Ikeda M, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Okusaka T.
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):408-12. PubMed ID: 20332676
    [Abstract] [Full Text] [Related]

  • 51. Molecular therapy for the treatment of hepatocellular carcinoma.
    Greten TF, Korangy F, Manns MP, Malek NP.
    Br J Cancer; 2009 Jan 13; 100(1):19-23. PubMed ID: 19018262
    [Abstract] [Full Text] [Related]

  • 52. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
    Herden U, Fischer L, Schäfer H, Nashan B, von Baehr V, Sterneck M.
    Transplantation; 2010 Jul 15; 90(1):98-9. PubMed ID: 20606568
    [No Abstract] [Full Text] [Related]

  • 53. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Llanos L, Bellot P, Zapater P, Pérez-Mateo M, Such J.
    Am J Gastroenterol; 2009 Jan 15; 104(1):257-8. PubMed ID: 19098892
    [No Abstract] [Full Text] [Related]

  • 54. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V, Barbare JC, Rosmorduc O, Groupe de travail carcinome hépatocellulaire Prodige-Afef.
    Gastroenterol Clin Biol; 2008 Jan 15; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract] [Full Text] [Related]

  • 55. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
    Faivre S, de Gramont A, Raymond E.
    Target Oncol; 2016 Aug 15; 11(4):565-7. PubMed ID: 26996978
    [No Abstract] [Full Text] [Related]

  • 56. Treatment of intermediate-stage hepatocellular carcinoma.
    Finn RS.
    Clin Adv Hematol Oncol; 2015 Aug 15; 13(8):501-3. PubMed ID: 26351811
    [No Abstract] [Full Text] [Related]

  • 57. Reply to M. Bouattour et al.
    Cainap C, McKee MD, Ricker JL.
    J Clin Oncol; 2015 Aug 01; 33(22):2486. PubMed ID: 26033815
    [No Abstract] [Full Text] [Related]

  • 58. Targeting STAT3 in hepatocellular carcinoma: sorafenib again….
    Rosmorduc O, Desbois-Mouthon C.
    J Hepatol; 2011 Nov 01; 55(5):957-9. PubMed ID: 21718664
    [No Abstract] [Full Text] [Related]

  • 59. Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
    Vitale A, Lombardi G, Ramirez Morales R, Cillo U.
    Dig Liver Dis; 2012 May 01; 44(5):361-2. PubMed ID: 22424640
    [No Abstract] [Full Text] [Related]

  • 60. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN, Flaherty KT.
    Clin Cancer Res; 2007 Jul 01; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.